Glutamatergic dysfunction--newer targets for anti-obsessional drugs

Sagnik Bhattacharyya; Koushik Chakraborty

doi:10.2174/157488907779561727

Glutamatergic dysfunction--newer targets for anti-obsessional drugs

Sagnik Bhattacharyya, Koushik Chakraborty

Psychosis Studies

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Despite widespread use and validation of their efficacy, about 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate courses of treatment with serotonin reuptake inhibitors (SRI) and even with the combination of pharmacotherapy and cognitive behaviour therapy a substantial number of patients remain dramatically symptomatic. Recently, there has been increasing interest in investigating glutamatergic dysfunction in OCD. Multiple lines of evidence point toward glutamatergic dysfunction being related to the pathophysiology of OCD, with glutamate modulating drugs being an alternative pharmacological strategy for treating OCD. In this article we focus in detail on the rationale for targeting glutamatergic agents as well as review the recent important patents for compounds that have emerged from these studies.

Original language	English
Pages (from-to)	47-55
Number of pages	9
Journal	Recent patents on CNS drug discovery
Volume	2
Issue number	1
DOIs	https://doi.org/10.2174/157488907779561727
Publication status	Published - 2007

Access to Document

10.2174/157488907779561727

Cite this

@article{813159691b134807adbba25e81b9de7f,

title = "Glutamatergic dysfunction--newer targets for anti-obsessional drugs",

abstract = "Despite widespread use and validation of their efficacy, about 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate courses of treatment with serotonin reuptake inhibitors (SRI) and even with the combination of pharmacotherapy and cognitive behaviour therapy a substantial number of patients remain dramatically symptomatic. Recently, there has been increasing interest in investigating glutamatergic dysfunction in OCD. Multiple lines of evidence point toward glutamatergic dysfunction being related to the pathophysiology of OCD, with glutamate modulating drugs being an alternative pharmacological strategy for treating OCD. In this article we focus in detail on the rationale for targeting glutamatergic agents as well as review the recent important patents for compounds that have emerged from these studies.",

author = "Sagnik Bhattacharyya and Koushik Chakraborty",

year = "2007",

doi = "10.2174/157488907779561727",

language = "English",

volume = "2",

pages = "47--55",

journal = "Recent patents on CNS drug discovery",

issn = "1574-8898",

publisher = "Bentham Science Publishers B.V.",

number = "1",

}

TY - JOUR

T1 - Glutamatergic dysfunction--newer targets for anti-obsessional drugs

AU - Bhattacharyya, Sagnik

AU - Chakraborty, Koushik

PY - 2007

Y1 - 2007

N2 - Despite widespread use and validation of their efficacy, about 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate courses of treatment with serotonin reuptake inhibitors (SRI) and even with the combination of pharmacotherapy and cognitive behaviour therapy a substantial number of patients remain dramatically symptomatic. Recently, there has been increasing interest in investigating glutamatergic dysfunction in OCD. Multiple lines of evidence point toward glutamatergic dysfunction being related to the pathophysiology of OCD, with glutamate modulating drugs being an alternative pharmacological strategy for treating OCD. In this article we focus in detail on the rationale for targeting glutamatergic agents as well as review the recent important patents for compounds that have emerged from these studies.

AB - Despite widespread use and validation of their efficacy, about 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate courses of treatment with serotonin reuptake inhibitors (SRI) and even with the combination of pharmacotherapy and cognitive behaviour therapy a substantial number of patients remain dramatically symptomatic. Recently, there has been increasing interest in investigating glutamatergic dysfunction in OCD. Multiple lines of evidence point toward glutamatergic dysfunction being related to the pathophysiology of OCD, with glutamate modulating drugs being an alternative pharmacological strategy for treating OCD. In this article we focus in detail on the rationale for targeting glutamatergic agents as well as review the recent important patents for compounds that have emerged from these studies.

U2 - 10.2174/157488907779561727

DO - 10.2174/157488907779561727

M3 - Article

C2 - 18221217

SN - 1574-8898

VL - 2

SP - 47

EP - 55

JO - Recent patents on CNS drug discovery

JF - Recent patents on CNS drug discovery

IS - 1

ER -

Glutamatergic dysfunction--newer targets for anti-obsessional drugs

Abstract

Access to Document

Fingerprint

Cite this